A Controlled Trial of Renal Denervation for Resistant Hypertension
New England Journal of Medicine2014Vol. 370(15), pp. 1393–1401
Citations Over TimeTop 1% of 2014 papers
Deepak L. Bhatt, David E. Kandzari, William W. O’Neill, Ralph B. D’Agostino, John M. Flack, Barry T. Katzen, Martin B. Leon, Minglei Liu, Laura Mauri, Manuela Negoita, Sidney A. Cohen, Suzanne Oparil, Krishna J. Rocha‐Singh, Raymond R. Townsend, George L. Bakris
Abstract
This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control. (Funded by Medtronic; SYMPLICITY HTN-3 ClinicalTrials.gov number, NCT01418261.).
Related Papers
- → Renal Denervation for Resistant Hypertension?(2014)64 cited
- → Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade(2020)22 cited
- → Drug Resistant Hypertension - No SIMPLE Way Out(2015)6 cited
- → Impact of renal denervation on 24-hour blood pressure pattern in patients with resistant hypertension(2019)5 cited
- → ENCOReD: Meta-Analysis of Renal Denervation in 10 European Expert Centers(2013)